gip and glp 1 drugs The dual glucose-dependent insulinotropic polypeptide (GIP) glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology Curious how GLP-1 and GIP
Description
The GLP-1R agonists are promising candidates for the treatment of obesity
This not only supports overall metabolic health but can also minimize hunger that results from blood sugar fluctuations
Methods We searched PubMed for studies published before March 2025
A new paradigm for treating to target with second-generation obesity medications
They found that current DPP-4 inhibitor usage did not correlate with an increased risk of these conditions compared to at least two oral antidiabetic drugs predominantly comprising metformin and sulfonylurea (3.6 vs
